LSE:GSKPharmaceuticals
GSK Hepatitis B Data Sparks Questions On Undervalued Shares And Risks
GSK (LSE:GSK) and Ionis reported positive results from two pivotal Phase 3 studies of bepirovirsen for chronic hepatitis B.
The treatment, designed as a finite six month regimen, achieved statistically significant and clinically meaningful functional cure rates.
If approved, bepirovirsen could become the first finite duration therapeutic option offering functional cure potential for chronic hepatitis B.
For investors tracking GSK at a share price of £17.955, this update on bepirovirsen...